Regeneron Pharmaceuticals (NASDAQ:REGN) Earns “Outperform” Rating from Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report released on Tuesday morning, Benzinga reports. Royal Bank of Canada currently has a $1,282.00 price objective on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on REGN. Guggenheim increased their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a buy rating in a report on Friday, August 2nd. Argus increased their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a buy rating in a report on Tuesday, June 25th. TD Cowen increased their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a buy rating in a report on Tuesday, July 23rd. Truist Financial reiterated a buy rating and issued a $1,200.00 price target (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. increased their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an overweight rating in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $1,111.30.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $1,150.19 on Tuesday. The firm has a market capitalization of $126.73 billion, a price-to-earnings ratio of 33.98, a PEG ratio of 3.97 and a beta of 0.12. Regeneron Pharmaceuticals has a 1 year low of $769.19 and a 1 year high of $1,211.20. The business has a 50 day simple moving average of $1,130.85 and a 200-day simple moving average of $1,030.53. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period last year, the company earned $8.79 EPS. Equities analysts forecast that Regeneron Pharmaceuticals will post 37.8 EPS for the current year.

Insider Activity

In other news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,467,684. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Bonnie L. Bassler sold 756 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,467,684. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Marion Mccourt sold 1,137 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the completion of the transaction, the executive vice president now owns 12,931 shares in the company, valued at $13,540,179.41. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,026 shares of company stock worth $11,498,705. 7.48% of the stock is currently owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after purchasing an additional 91,956 shares in the last quarter. Capital World Investors boosted its position in shares of Regeneron Pharmaceuticals by 0.5% in the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after purchasing an additional 23,146 shares in the last quarter. Capital International Investors boosted its position in shares of Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after purchasing an additional 213,038 shares in the last quarter. Putnam Investments LLC boosted its position in shares of Regeneron Pharmaceuticals by 2.1% in the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after purchasing an additional 24,329 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Regeneron Pharmaceuticals by 25.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after purchasing an additional 184,561 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.